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Abstract
Importance—False-positive mammograms, a common occurrence in breast cancer screening
programs, represent a potential screening harm that is currently being evaluated by the United
States Preventive Services Task Force.
Objective—To measure the impact of false-positive mammograms on quality of life by
measuring personal anxiety, health utility and future screening attitudes.
Design—Longitudinal Digital Mammographic Imaging Screening Trial (DMIST) quality-of-life
sub-study telephone survey shortly after screening and one year later.
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Participants—Randomly-selected DMIST participants with positive and negative
mammograms.
Exposure(s) for observational studies—Mammogram requiring follow-up testing or
referral without a cancer diagnosis.
Main Outcome(s) and Measure(s)—The Spielberger State-Trait Anxiety Index short-form
(STAI-6) and the EuroQol EQ-5D with United States scoring. Attitudes toward future screening
measured by women’s self-report of future intention to undergo mammography screening and
willingness to travel and stay overnight to receive a hypothetical new mammogram that would
detect as many cancers with half the false-positives.
Results—Among 1,450 eligible women invited to participate, 1,226 women (85%) were enrolled
with follow-up interviews obtained for 1,028 (84%). Anxiety was significantly higher for women
with false-positive mammograms (STAI-6:35.2 vs. 32.7), but health utility did not differ and there
were no significant differences between groups at one year. Future screening intentions differed
by group (26% vs. 14% more likely in false-positive vs. negative); willingness to travel and stay
overnight did not (11% vs. 10% in false-positive vs. negative). Future screening intention was
significantly increased among women with false-positive mammograms (OR: 2.12; 95%CI:1.54,
2.93), younger age (OR:2.78; 95%CI:1.5,5.0) and poorer health (OR: 1.63; 95%CI:1.09, 2.43).
Women’s anticipated high-level anxiety regarding future false-positives was associated with
willingness to travel overnight (OR: 1.94; 95%CI:1.28, 2.95).
Conclusions and Relevance—False-positive mammograms were associated with increased
short-term anxiety, but no long-term anxiety and no measurable health utility decrement. False-
positive mammograms increased women’s intention to undergo future breast cancer screening and
did not increase women’s stated willingness to travel to avoid a false-positive mammogram. Our
finding of time-limited harm following false-positive screening mammograms is relevant for
healthcare providers who counsel women on mammography screening and for screening guideline
development groups.
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A substantial proportion of women who undergo routine screening mammography over a
10-year period will experience a false-positive mammogram, requiring additional work-up
to rule out breast cancer.1-3 False-positive mammograms leading to benign unnecessary
biopsies compared with the number of cancers detected contributed to the 2009 changes in
the U.S. Preventive Services Task Force (USPSTF) breast cancer screening guidelines.4
Instead of recommending routine screening among 40-49 year old women, the USPSTF
recommends that women in their 40s discuss the pros and cons of mammography screening
with their healthcare providers before deciding whether to initiate screening. This
recommendation acknowledges that individual women’s preferences regarding the balance
of screening benefits vs. harms, which include false-positive mammograms, may differ. As
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the USPSTF re-evaluates the evidence for breast cancer screening, the harms of screening
are among the questions to be addressed in their systematic evidence review. 4
While there is a growing literature on how women view false-positive screening
mammograms, 3,5-23 few studies have attempted to assess the impact of false-positive results
on generic measures which allow comparison to a broad range of health outcomes. To
include such a harm in a societal cost-effectiveness analysis, the impact of false-positive
screening mammograms on generic health utility, using a scale where 0 represents being
dead and 1 represents perfect health, is needed to compute cost-effectiveness results which
can be compared to other health care interventions. 24 These facts, combined with early
digital mammography screening studies, 25-29 which suggested that digital mammography
may yield fewer false-positive exams than screen-film mammography, led to inclusion of a
quality-of-life (QoL) sub-study in the American College of Radiology Imaging Network
Digital Mammographic Imaging Screening Trial (DMIST). 30 The QoL sub-study was
designed to characterize the personal anxiety, disutility and personal time costs associated
with work-up of positive screening mammograms. Personal time costs of mammography
screening outcomes in DMIST were reported and used in the DMIST cost-effectiveness
analysis. 31 In this paper, we report DMIST QoL sub-study results that characterize the
impact of false-positive screening mammograms on personal anxiety, health utility, and
attitudes toward future screening.
METHODS
Digital Mammographic Imaging Screening Trial (DMIST)
DMIST was funded by the National Cancer Institute and conducted by ACRIN as described
in detail elsewhere.30 In brief, DMIST’s primary aim was to compare the diagnostic
accuracy of digital mammography relative to screen-film mammography. 32,33 Secondary
aims included an economic evaluation of digital mammography31 and an assessment of the
impact of false-positive screening mammograms on quality of life.
To be eligible for DMIST, women had to present for screening, agree to undergo a follow-
up mammogram, and consent to study participation. Women were excluded if they had a
focal dominant lump or bloody or clear nipple discharge, a history of breast cancer treated
with lumpectomy, breast implants, or believed they might be pregnant. Eligible women
received both digital and screen-film mammograms, which were read independently by
different radiologists.
DMIST QoL Sub-study Participants
The sub-study was conducted by telephone survey and included two groups of women: (1) a
random sample of DMIST participants with a positive screening mammogram, defined as
any mammogram where additional work-up or consultation was recommended; and (2) a
sample of women with a negative screening mammogram. To ensure a comparable number
of participants with positive and negative mammograms from each site, for each woman
selected with a positive screening mammogram, a woman from the same institution who had
a negative screening mammogram and who was of similar age (within 5 years) was also
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selected for participation. Women diagnosed with breast cancer at any time during DMIST
were ineligible and were excluded.
Measures
Anxiety—The Spielberger State-Trait Anxiety Inventory (STAI) is a widely used measure
of general anxiety that includes both a state scale and a trait scale.34 In the present study we
are interested in state anxiety--anxiety of the moment as experienced by the person. To
measure this we used a validated 6 question short-form of the STAI state scale (STAI-6),
which yields a score between 20 (least anxious) and 80 (most anxious). 35
Health Utility—To characterize general health-related quality of life we used the validated
EuroQol EQ-5D instrument which consists of 5 questions, one each about mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression.36 Each question has three
possible responses categorizing degree of problem with the particular aspect of health
ranging from 1 (no problem) to 3 (extreme problem). The 5 questions and 3 response
categories are used to define 245 distinct health states. Scoring using U.S. preference
weights assigns health state values ranging from −0.11(worst health for those with extreme
problems in all five areas) to 1.0 (best health for state for those with no problem in any
area). 37
A current health rating scale (RS) asked “On a scale from 0 to 100 where 0 represents death
or the worst health you can imagine and 100 represents perfect health or the best health you
can imagine, how would you rate your health during the past 4 weeks?”
Breast-related Resource Use—At follow-up, women were asked “since your
mammogram approximately 12 months ago (date provided), have you received medical care
for any breast-related concerns?” Women who answered affirmatively were read a list of
tests, procedures and health provider visits that some women undergo after a mammogram
and were asked which they had undergone.
Future Screening Attitudes—Women were asked to think about “how your breast-
related care in the past year may change your future use of screening mammography” and to
choose the statement that best represented their feelings at the time of the follow-up survey.
Response choices were: “I am less likely than a year ago to undergo screening
mammography in the future”; “My use of screening mammography will not change”; “I am
more likely than a year ago to undergo screening mammography in the future.”
Two questions asked women their opinion about new types of mammograms that may be
developed in the future. A willingness-to-pay-to-avoid approach was used to assess how
women valued false-positive screening mammograms. This was implemented by asking
about the duration of travel women would be willing to undertake to gain access to a
hypothetical new type of mammography that would produce fewer false-positive exams
while detecting just as many cancers. This survey item was developed for the present study
and was modeled on the waiting-time tradeoff developed to value transient health states
encountered in radiological cost-effectiveness analyses, 38 with travel serving as a metaphor
for lost time.
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Women were also asked to imagine they could choose between two new types of
mammograms that are just as accurate as those today. One type resulted in fewer false-
positive mammograms while the other type resulted in less breast compression. (See
appendix for details). Development of the travel and new mammogram type survey items
was informed by focus groups of women who had experienced false-positive screening
mammograms.
Telephone Interview Schedule—Telephone interviews were conducted shortly after the
baseline mammogram and approximately one year later. At both times, the interview
included the STAI -6, EQ-5D and the current health rating scale.
The baseline interview was intended to occur after notification of the need for further work-
up and before work-up completion—during what we define as the “active work-up
window.” This was not always possible. Based on follow-up data on the date of subsequent
breast-related medical care, we categorized baseline interviews as occurring during or after
the active work-up window. Women interviewed after the active work-up window were
considered to have had “resolved” false-positive mammograms at the time of the baseline
interview. We hypothesized that, compared to women with negative screening
mammograms, anxiety would be highest and quality of life lowest for women with positive
screening exams who were interviewed in the active work-up window (i.e., before the false-
positive mammogram was resolved). We further hypothesized that elevated anxiety and
reduced health utility associated with a false-positive mammogram would be transient such
that at follow-up there would be no differences between those with positive and negative
screening mammograms.
At the second interview, additional information on breast-related resource utilization and
attitudes toward future screening mammography was collected.
Statistical Analysis
Characteristics of participants were summarized using means and proportions, with
comparisons between women with positive versus negative mammograms made using t-tests
and chi-squared tests. To assess the impact of the positive mammogram on anxiety and
health utility, the change between baseline and follow-up scores were compared between
those with positive and negative mammograms. In logistic regression analyses, we explored
factors associated with women’s self-report of their increased likelihood to undergo future
breast cancer screening and with the odds of being willing to travel overnight to avoid a
false-positive exam. Variables considered included age, breast cancer risk, baseline
mammogram positivity, need for biopsy, anticipated anxiety regarding future false positive
mammograms, race/ethnicity and institution.
RESULTS
Among 1,450 eligible women invited to participate, 1,226 women (85%) from 22
institutions were enrolled in the QoL sub-study and follow-up interviews were obtained for
1,028 participants (84%). Women with false positive mammograms tended to be younger,
but did not differ on any other characteristics (Table 1).
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At baseline, there were significant differences in anxiety between women with positive and
negative exams, but no statistically significant differences in EQ-5D or current health RS
(Table 2). At follow-up, a significant decline in anxiety was noted (mean STAI-6 difference
- 1.53, 95%CI: −2.70, −0.35) among women with positive mammograms (Table 2). Women
with negative mammograms were found to have a modest, but significant, decline in RS at
follow-up (RS mean difference, −1.22, 95%CI: −2.34,−0.10).
Use of breast-related care reported one-year following the initial screening exam differed by
positivity status for all categories except clinical breast exam (Table 3). Biopsy procedures
were used in 15% of women with a false-positive mammogram compared with 1% of
women with negative mammograms. Among women with a false-positive exam, anxiety
was reported as moderate or higher by 51% and as extreme by 5%.
Women’s plans to undergo mammography within the next two years did not differ by
screening outcome, but significantly more women who experienced a false-positive
mammogram characterized themselves as “more likely” to undergo future breast cancer
screening (26%) than women who had a negative mammogram (14%) (Table 4). However,
there were no differences noted in women’s attitudes toward the anticipated anxiety they
would feel if they were to experience a positive mammogram in the future. A majority of
women in each group (62% of negative and 64% of false positive groups) felt they would
experience anxiety that was moderate or worse if a false positive mammogram were to occur
in the future; and a substantial proportion anticipated feeling high anxiety (27%
characterizing anticipated anxiety as “a lot” or “extreme” in each group).
Women’s experience of a false-positive mammogram compared to women who had negative
mammograms did not influence their willingness to travel to avoid a false-positive
mammogram in the future, with the vast majority of women in both groups being willing to
travel up to 4 hours to avoid a false-positive mammogram. A small minority in each group
was willing to travel and stay overnight to avoid a false positive mammogram (11% of
negative and 10% of false positive groups). When women were asked to choose between a
new type of mammography that would either avoid breast compression or avoid false-
positive mammograms, the vast majority (81%) chose the technology with fewer false
positives.
When correlates of future breast cancer screening intention were examined, we found that
women with a false-positive baseline mammogram, lower quartile health utility, or age
under 65years were more likely to report they would undergo future screening (Table 5). In
multivariable analyses, a false-positive mammogram more than doubled women’s stated
intention to utilize future screening (OR, 2.17, 95%CI: 1.57, 3.01). Willingness to travel and
stay overnight to avoid a false-positive mammogram did not vary by positivity but was
associated with women’s reports of anticipated anxiety if they were to experience a false-
positive mammogram in the future (Table 5).
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The DMIST QoL sub-study provides evidence that women with a false-positive
mammogram initially experienced a significant increase in anxiety, and that these effects
were transient and were not measurable using the EQ-5D questionnaire or current health
rating scale. A small proportion of women were willing to travel and stay overnight to
undergo screening with a hypothetical modality that would have fewer false-positive
findings, but this willingness was not influenced by experience of a false-positive
mammogram. Instead, willingness to travel was associated with women’s anticipated
feelings of anxiety surrounding a future false-positive mammogram. Women who
anticipated feeling more than moderate anxiety were nearly twice as likely to report a
willingness to travel and stay overnight relative to women who anticipated feeling lesser
anxiety. Our results regarding the transient anxiety associated with false positive
mammograms may provide useful information for clinicians who counsel individual women
regarding the decision of whether to initiate breast cancer screening and for policy-makers
assessing the clinical effectiveness of mammography screening.
While there is concern that the health and psychological burden of false-positive
mammograms may not be justified when weighed relative to the few additional breast
cancers that routine screening would confer among younger women, we found only a
transient impact of a false-positive mammogram on anxiety. Our finding differs from recent
reports of longer-term impact of false-positive mammograms on specific psychological
outcomes.21-23 However, it is important to note that the ongoing harms reported in the
literature are related primarily to breast-cancer specific outcomes rather than general
psychological measures such as the general anxiety measure used in our study. Whether one
should expect harms that are only measurable when framed in terms of a specific disease to
affect a general anxiety or health-utility measure is an open question. An important feature
of the two generic measures, STAI-6 and EQ-5D, used in our study is the ability to compare
potential harms associated with breast cancer screening to those associated with a broad
range of other health care practices.
In addition to the transient impact on anxiety, we also provide evidence that women are
motivated to avoid false-positive mammograms. It is notable that a large proportion of
women were willing to travel up to 4 hours to receive a hypothetical new type of
mammogram that would be just as good at finding cancer, but would result in fewer false-
positive mammograms. Further supporting women’s interest in avoiding false-positive
mammograms is the fact that when given the choice between two new types of
mammograms—one with reduced false positives and one with reduce breast compression—
that the majority of women in our study chose the type with fewer false positives.
Our study also characterized the anxiety and discomfort imposed by the health care visits
and procedures used to resolve positive screening mammograms. Although anxiety and
discomfort were significantly higher among women with false-positive mammograms
compared to women with negative mammograms, these findings appeared to have no impact
on women’s plans to have a mammogram in the next 2 years—something that 94% of
women intended to do. In contrast, women’s intention to use breast cancer screening in the
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future (i.e., self-characterization as being more likely to undergo future breast cancer
screening) was increased by 2-fold among women who experienced a false-positive
mammogram. The reasons for this are unclear, but a meta-analysis of observed screening
practices following a positive mammogram has similarly concluded that women in the U.S.
who experience a false-positive mammogram are significantly more likely to participate in
future mammography screening.11
QoL sub-study results were used to estimate previously reported economic time costs
associated with follow-up of screening mammograms and were incorporated into the cost-
effectiveness analysis of digital mammography.31 In this paper, we have provided further
information on use of follow-up tests. Not surprisingly, some women with negative
screening mammograms reported use of breast-related medical services within the year
following their screening mammogram (e.g., additional imaging in 5% and breast biopsy in
1%), but use of such services were associated with lower levels of anxiety and less
discomfort than was reported among women with false-positive mammograms.
The DMIST cost-effectiveness analysis did not adjust for a quality of life/health utility loss
when estimating quality-adjusted life years (QALYs) for women with false-positive
screening exams, a decision supported by our results showing no measurable impact with
EQ-5D. 31 Nonetheless, it is important to recognize that measures such as the EQ-5D, which
are appropriate for use in societal cost-effectiveness studies, are of limited value in clinical
settings where individual women must consider how they value potential screening
outcomes when weighing the benefits and harms of breast cancer screening. In this context,
it is noteworthy that there were no differences reported in DMIST between women with
false-positive mammograms and those with negative mammograms concerning the amount
of anxiety they said they would anticipate feeling if they were to encounter a positive
screening mammogram in the future. However, 27% of women reported that they would feel
more than a moderate amount of anxiety/concern (i.e., a lot of anxiety/concern or extreme
anxiety/concern) if such a screening outcome were to occur. Thus, it seems prudent for
women and their healthcare providers to consider the potential outcomes of screening when
coming to a decision on the best course of action for each individual woman. In addition,
studies to improve breast screening practices by finding approaches that reduce such anxiety
are also warranted.
Several limitations to our study deserve comment. First, we intended to interview women
during the active work-up window but this was not always achieved. As a result, many
women were interviewed after work-up was completed. Nonetheless, we were able to
document heightened anxiety associated with false-positive mammograms. We did not
document any impact on overall health utility using the EQ-5D preference-based measure
that is appropriate for use in estimating QALYs. This may be due to limitations in the
EQ-5D descriptive system, which combines the rating of anxiety and depression together at
only 3 levels: 1) I am not anxious or depressed; 2) I am moderately anxious or depressed;
and 3) I am extremely anxious or depressed; due to general insensitivity of EQ-5D to small
changes in health of healthy people; or it may suggest a relatively low anxiety effect for
false-positive mammograms. In addition, the majority of participants rated their health at the
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ceiling of the EQ-5D descriptive system at baseline in both the false-positive (n=272/494,
55%) and negative groups (n=293/531, 55%) groups.
Second, the attitudes of DMIST volunteers may not be representative of the general
population of women eligible for breast cancer screening. One might expect that DMIST
participants’ enthusiasm for screening may be higher than in a general population, a
conjecture supported by the fact that 94% of women reported their intention to undergo
breast cancer screening with mammography again within two years. However, attitudes
toward cancer screening in the US have generally been documented as highly favorable. 39
We conclude that false-positive mammograms are associated with a measurable, small and
transient impact on personal anxiety and that further research should address opportunities
for reducing this anxiety. While the impact of false-positive mammograms on health utility
for estimating QALYs is not measurable using the current EQ-5D instrument, it is clear that
women, regardless of whether or not they experienced a false-positive, are willing to invest
the time necessary for travel to avoid future false-positive mammograms. The fact that
women’s anticipated anxiety about future false-positive mammograms was a correlate of
willingness to travel and stay overnight to avoid a false-positive mammogram, but that the
actual experience of a false positive was not, further highlights opportunities for educating
women about screening outcomes. While health utilities were not measurably affected, the
experience of a false-positive mammogram did increase women’s intentions to undergo
breast cancer screening in the future. Ongoing studies of breast cancer screening processes
of care through NCI’s PROSPR (Population-based Screening Optimizing Screening through
Personalized Regimens) initiative may further elucidate the frequency and sequelae of false
positive screening mammograms. Meanwhile, our report on women’s experience of false-
positive mammograms may provide useful information for those counseling women
regarding the decision to undergo mammography screening and for screening guideline
development groups.
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Appendix: Follow-up interview used to assess attitudes toward future
screening
Interviewer Instructions are italicized. Read the next set of questions that ask about your
plans for and feelings about future breast-related care.
1. Please think about how your breast-related care in the past year may change your future
use of screening mammography. Which statement best represents how you feel today?
2. Are you planning on having a screening mammogram within the next 2 years?
3. After a screening mammogram, additional tests and procedures are sometimes needed
because the mammogram mistakenly indicates that breast cancer may be present when it is
not. These are known as “false positive mammograms.” How much anxiety/concern would
you have if additional tests or procedures were required after your next screening
mammogram?
READ: The last 2 questions ask your opinion about new types of mammograms that may be
developed in the future.
4. Imagine there is a new type of mammogram that is just as good at finding breast cancer as
standard mammograms are today. This new mammogram results in fewer false positives
(i.e., only one-half as many women who don’t have breast cancer will have to have
additional testing after a mammogram), but this mammogram is not available where you
usually go for your mammogram. If you wish to receive the new mammogram, you must
plan for additional travel time to go to another medical center where they have this new type
of mammogram.
Would you choose to have the new mammogram instead of a standard screening
mammogram if you had to travel for:
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5. Imagine that there are two new types of mammograms. Both are as accurate as
mammograms we have today. Imagine you have to choose between the two new types of
mammograms. One type of mammogram results in fewer false positives (i.e., fewer women
who do not have breast cancer will have to have additional testing), the other type of
mammogram requires less breast compression but has the same number of false positives as
today’s methods. Which would you choose to have?
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Table 1







<50 years 424 (41) 206 (39) 218 (44)1
50-64 years 462(45) 260 (49) 202 (41)
65+ years 142(14) 68 (13) 74 (15)
Lifetime Breast
Cancer Risk
<5% 160 (16) 76 (14) 84 (17)
5-9.9% 501 (49) 269 (50) 232 (47)
10%+ 367 (36) 189 (35) 178 (36)
Race
White 843 (82) 444 (83) 399 (81)
Black 127 (12) 59 (11) 68 (14)
Hispanic/Latina 37 (4) 20 (4) 17 (3)
Other 21(2) 11 (2) 10 (2)
Health Rating
Excellent 337 (33) 189 (35) 148 (30)
Very Good 444 (43) 220 (41) 224 (45)
Good 194 (19) 103 (19) 91 (18)
Fair 42 (4) 16 (3) 26 (5)
Poor 10 (1) 5 (1) 5 (1)
1
p<0.05
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Table 3







 Any additional imaging** 24 (5) 327 (66)
 Additional mammogram** 20 (4) 280 (57)
 Ultrasound** 7 (1) 141 (29)
 Breast MRI 3 (1) 6 (1)
Clinical Exam Visits
 Any clinical exam visit 283 (44) 273 (55)
 Clinical breast exam 282 (53) 267 (54)
 Surgical consult** 6 (1) 36 (7)
 Other clinical exam visit 6 (1) 5 (1)
Any Biopsy **
 Biopsy or Needle Aspiration 6 (1) 72 (15)
Anxiety Level associated with additional care,+
 No anxiety/concern 138 (48) 66 (17)
 A little anxiety/concern 104 (36) 128 (33)
 Moderate anxiety/concern 32 (11) 107 (27)
 A lot of anxiety/concern 10 (4) 74 (19)
 Extreme anxiety/concern 3 (1) 18 (5)
Discomfort Level associated with additional care,+
 No Discomfort 159 (56) 102 (26)
 A little discomfort 83(29) 152(39)
 Moderate discomfort 33(12) 90 (23)
 A lot of discomfort 8 (3) 31 (8)
 Extreme discomfort 3 (1) 17 (4)
**
p<0.001 for comparison between negative and false positive groups.
+
Note that data were obtained for these items from 287/534 (53%) women with negative mammograms and 393/494 (80%) women with a false-
positive mammogram and comparisons are based on a chi-squared test of association between response categories and positivity with p<0.001.
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Table 4






Intention to Have Mammography in Next 2 years
 Yes 499 (94) 462 (94)
 No 31 (6) 25 (5)
 Don’t know/refuse 2 (0) 5 (1)
Intention to Use Future Screening **
 Less likely 5 (1) 11 (2)
 Unchanged 449 (84) 355 (72)
 More likely 76 (14) 127 (26)
Choice of New Mammogram
 Fewer false positives 432 (81) 407 (82)
 Less breast compression 94 (18) 77 (16)
Anxiety if Future False Positive
 No anxiety/concern 35 (7) 33 (7)
 A little anxiety/concern 170 (32) 165 (33)
 Moderate anxiety/concern 185 (35) 156 (32)
 A lot of anxiety/concern 120 (23) 104 (21)
 Extreme anxiety/concern 22 (4) 31 (6)
Willingness to Travel to Avoid False Positive
 Less than 30 minutes 87 (16) 63 (13)
 Up to 4 hours 355 (67) 349 (71)
 Up to overnight stay 30 (6) 30 (6)
 Overnight 56 (11) 49 (10)
**
<0.0001
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Table 5
Correlates of greater intention to use future screening and willingness to travel and stay overnight to avoid a





Intention to Use Future Breast Cancer Screening
 FP screening mammogram 2.07 (1.51, 2.84) 2.12 (1.54, 2.93)
 Age younger than 65 2.44 (1.39, 4.35) 2.78 (1.56, 5.00)
 EQ-5D baseline (good1 vs. perfect2) 1.00 (0.69, 1.46) 1.04 (0.71, 1.52)
 EQ-5D baseline (lower quartile3 vs. perfect) 1.52 (1.03, 2.24) 1.63 (1.09, 2.43)
Willingness to Travel and Stay Overnight to Avoid a False-Positive Mammogram
 FP screening mammogram 0.93 (0.62, 1.40) 0.93 (0.62, 1.40)
 Anticipated high anxiety4 if future FP 1.94 (1.28, 2.94) 1.94 (1.28, 2.95)
1
EQ-5D value below 1.0 and above 0.8271.
2




Self-report of “a lot” or “extreme” anxiety/concern.
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